Navigation Links
Heska Announces Q310 Results
Date:11/15/2010

LOVELAND, Colo., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA, "Heska" or the "Company") today reported financial results for its third quarter ended September 30, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20000622/HESKALOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)

"These results exceed our revenue expectations and most recent revenue guidance.  We had a particularly strong quarter in our Other Vaccines, Pharmaceuticals and Products segment where the USDA validated an improved process for our line of cattle vaccines, allowing us to ship a significant quantity of product in a category which had previously been on hold due to regulatory discussions," said Robert Grieve, Heska's Chairman and CEO.  "As we have reported over the course of 2010, we faced a difficult year-over-year comparison in our Core Companion Animal Health segment as we are no longer selling the old line of handheld blood analysis instruments and affiliated consumables.  This product area accounted for over $2.7 million in revenue in the third quarter of 2009, with no such revenue in the third quarter of 2010."

Investor Conference CallManagement will conduct a conference call on Monday, November 15, 2010 at 9:00 a.m. MST (11:00 a.m. EST) to discuss the third quarter 2010 financial results.  To participate, dial (800) 762-8779 (domestic) or (480) 629-9771 (international); the conference call access number is 4371990.  The conference call will also be broadcast live over the Internet at http://www.heska.com.  To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software.  Telephone replays of the conference call will be available for playback until November 29, 2010.  The telephone replay may be accessed by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international).  The webcast replay may be accessed from Heska's home page at www.heska.com until November 29, 2010.

About HeskaHeska Corporation (Nasdaq: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products.  Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines.  The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.  For further information on Heska and its products, visit the company's website at www.heska.com.

Forward-Looking StatementsThis announcement contains forward-looking statements regarding Heska's future financial and operating results.  These statements are based on current expectations and are subject to a number of risks and uncertainties.  Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes.  For example, while Heska generated positive net income this quarter, there can be no assurance Heska will generate positive net income, or avoid a loss, in any future period.  In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to Heska's ability to maintain regulatory compliance for products it sells; risks related to competition and Heska's ability to compete economically in the marketplace; uncertainties related to the performance of third parties to whom Heska has granted substantial marketing rights including, but not limited to, Schering-Plough Animal Health Corporation; risks related to Heska's ability to maintain its listing on the NASDAQ Capital Market; uncertainties related to Heska's ability to market and sell its products successfully and economically; uncertainties related to Heska's ability to generate cash flow in any future periods; risks related to Heska's reliance on third-party suppliers, which is significant, including Heska's ability to meet its commitments to such suppliers; risks related to Heska's reliance on its revolving line of credit and Heska's ability to meet financial and other covenants to maintain access to such line of credit; uncertainties related to the impact of transfer restrictions on Heska's stock, which were approved by Heska stockholders at Heska's Annual Meeting of Stockholders on May 4, 2010; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010.Financial Table Follows:Consolidated Statements of Operations

In Thousands, Except per Share Amounts

(unaudited)Three Months EndedSeptember 30,Nine Months Ended
September 30,2009201020092010Revenue, net:Core companion animal health

$

16,89214,144$

51,908$

43,667Other vaccines, pharmaceuticals and products2,6583,4916,4126,769Total revenue, net 19,55017,63558,32050,436Cost of revenue12,13011,04236,49631,791Gross profit7,4206,59321,82418,645Operating expenses:Selling and marketing3,6953,91211,07511,604Research and development4574551,3081,300General and administrative2,1091,8616,2556,071Total operating expenses6,2616,22818,63818,975Operating income (loss) 1,1593653,186(330)Interest and other (income) expense, net(13)(118)193177Income (loss) before income taxes1,1724832,993(507)Income tax expense (benefit)4292421,211(253)Net income (loss)

$

743$

241$

1,782$

(254)Basic net income (loss) per share

$

0.01$

0.00$

0.03$

(0.00)Diluted net income (loss) per share

$

0.01$

0.00$

0.03$

(0.00)Shares used for basic net income (loss) per share52,12352,23752,04952,188Shares used for diluted net income (loss) per share52,19252,37652,06052,188Balance Sheet Data

In Thousands (unaudited)December 31,2009September 30,2010Cash and cash equivalents$

5,400$

5,745Total current assets28,49328,358Total assets64,13464,433Line of credit4,2014,989Current portion of long-term debt381-Total current liabilities14,10714,366Stockholders' equity45,05545,277
'/>"/>

SOURCE Heska Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer
2. Heska to Present at SunTrust Robinson Humphrey 1st Annual Veterinary Conference
3. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2009 Earnings Conference Call Webcast
4. Heska Announces Extension of Credit Agreement With Wells Fargo
5. Heska Announces Supply Agreement With Roche Diagnostics
6. Heska Announces Launch of New Website
7. Heska Announces Q309 Results
8. Parascript Announces AccuDetect 4.0, Computer-Aided Detection (CAD) for Mammography
9. Adeona Announces Third Quarter 2010 Financial Results and Achievements
10. BioWa Announces License of POTELLIGENT® Technology to Agensys
11. Dehaier Medical Announces Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):